CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 2, 2010, Pages 240-247

  Mandel, Ronald J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERE 110; CHOLINESTERASE INHIBITOR; PARVOVIRUS VECTOR; RECOMBINANT NERVE GROWTH FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; BLOOD BRAIN BARRIER; BRAIN METABOLISM; BRAIN NERVE CELL; CELL SURVIVAL; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; HYGROMA; NONHUMAN; OLIVARY NUCLEUS; REVIEW; SEROTYPE; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

AGED; ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NERVE GROWTH FACTORS;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 77950838482     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. The cholinergic system and EEG slow waves. Riekkinen P, Buzsaki G, Riekkinen Jr P, Soininen H, Partanen J ELECTROENCEPHALOGR CLIN NEUROPHYSIOL 1991 78 2 89-96
2. Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats. Kwo-On-Yuen PF, Mandel R, Chen AD, Thal LJ EXP NEUROL 1990 108 3 221-228
3. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fmbria formix transection. Williams L, Varon S, Peterson G, Wictorin K, Bjorkland A, Gage F PROC NATL ACAD SCI USA 1986 83 23 9231-9235
4. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Fischer W, Wictorin K, Bjorkland A, WilliAMs RA, Varon S, Gage FH NATURE 1987 329 6134 65-68
5. Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Haroutunian V, Kanof PD, Davis KL BRAIN RES 1989 487 200-203
6. The cholinergic hypothesis of geriatric memory dysfunction. Bartus RT, Dean RL, Beer B, Lippa AS SCIENCE 1982 217 4558 408-414
7. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Smith DE, Roberts J, Gage FH, Tuszynski MH PROC NATL ACAD SCI USA 1999 96 19 10893-10898
8. Ceregene confrms treatment of first patient in phase I study of Alzheimer's disease gene therapy: First patient ever treated in human gene therapy study for Alzheimer's disease. Ceregene Inc PRESS RELEASE 2001 April 11
9. A non-invasive system for delivering neural growth factors across the blood-brain barrier: A review. Granholm AC, Albeck D, Backman C, Curtis M, Ebendal T, Friden P, Henry M, Hoffer B, Kordower J, Rose GM, Soderstrom S et al REV NEUROSCI 1998 9 1 31-55
10. Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fmbria-fornix lesion-induced degeneration. Mandel RJ, Gage FH, Clevenger DG, Spratt SK, Snyder RO, Leffi SE EXP NEUROL 1999 155 1 59-64
11. Ceregene licenses genes from Genentech for neurological gene therapies. Ceregene Inc PRESS RELEASE 2003 March 26
12. Ceregene announces issuance of broad patent for neurologic gene therapy. Ceregene Inc PRESS RELEASE 2004 February 11
13. Ceregene confrms plans to further develop Alzheimer's disease gene therapy. Ceregene Inc PRESS RELEASE 2004 April 29
14. Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Mandel RJ, Burger C CURR OPIN MOL THER 2004 6 5 482-490
15. Pre-CLINical safety and efficacy studies of adeno-associated virus (AAV)-based delivery of human β-nerve growth factor (NGF) to basal forebrain cholinergic neurons (BFCNS). Brandon EP, Bishop KM, Hofer EK, Brown L, Kruegel B, Austin M, Printz MA, Gasmi M, Ostrove JM, Tuszynski MH, Bartus RT ABSTR SOC NEUROSCI 2004 34 San Diego Abs 216.18
16. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA ARCH NEUROL 2003 60 8 1119-1122
17. A phase 1 Clinical trial of nerve growth factor gene therapy for Alzheimer disease. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G et al NAT MED 2005 11 5 551-555
18. Memory Pharmaceuticals announces positive preliminary phase 1 cognitive data for MEM 3454. Memory Pharmaceuticals Corp PRESS RELEASE 2006 February 21
19. A 2-year study in monkeys to evaluate expression, bioactivity, and safety/tolerability of CERE-110, an AAV2-based vector encoding NGF for the potential treatment of Alzheimer's disease. Bishop KM, Herzog CD, Zeller JR, Printz MA, Gasmi M, Brandon EP, Boyd RB, Bartus RT ABSTR SOC NEUROSCI 2006 36th Atlanta Abs 674.6/MM7
20. Memory Pharmaceuticals commences phase 2a trial of MEM 3454 in Alzheimer's disease. Memory Pharmaceuticals Corp PRESS RELEASE 2007 March 13
21. Ceregene presents interim phase 1 Clinical data of CERE-110 for the treatment of Alzheimer's disease. Ceregene Inc PRESS RELEASE 2007 May 02
22. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Herzog CD, Dass B, Gasmi M, Bakay R, Stansell JE, Tuszynski M, Bankiewicz K, Chen EY, Chu Y, Bishop K, Kordower JH et al 2008 16 10 1737-1744 MOL THER
23. Alzheimer's disease facts and fgures. Alzheimer's Association ALZHEIMER DEMENTIA 2009 5 3, 2009, 234-270
24. Ceregene presents additional Clinical data from phase 2 trial of CERE-120 for Parkinson's disease. Ceregene Inc PRESS RELEASE 2009 May 27
25. Interim data from a phase 1 Clinical trial of AAV-NGF (CERE-110) gene delivery in Alzheimer's disease. Arvanitakis Z, Tuszynski MH, Bakay R, Arends D, Potkin S, Bartus R, Bennett D NEUROLOGY 2007 68 12 Abs P05.071
26. Analyses of a phase 1 Clinical trial of adeno-associated virus-nerve growth factor (CERE-110) gene therapy in Alzheimer's disease. Bakay RAE, Arvanitakis Z, Tuszynski M, Potkin S, Bartus R, Bennett D NEUROSURGERY 2007 61 1 Abs 866
27. Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Bishop KM, Hofer EK, Mehta A, RAMirez A, Sun LW, Tuszynski M, Bartus RT EXP NEUROL 2008 211 2 574-584
28. CERE-110, an AAV2-based vector to deliver NGF, provides trophic activity to basal forebrain cholinergic neurons in rats and cynoMOLgous monkeys. Bishop KM, Hofer K, Rius D, Mehta A, Lawandry S, Brown L, Kruegel B, Gasmi M, Tuszynski M, Bartus RT MOL THER 2004 9 S1 Abs 527
29. Biodistribution and safety profile of CERE-110 (AAV2-NGF) delivered to the rodent brain. Landers M, Austin M, Kwok K, Ketchum E, Lin R, Manlapaz L, Mehta A, Fernandez J, Gasmi M, Vacante D, Bartus RT et al MOL THER 2004 9 S1 Abs 539-S204
30. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Jonhagen ME, Nordberg A, AMberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger A, Shigeta M, Theodorsson E, Viitanen M et al DEMENT GERIATR COGN DISORD 1998 9 5 246-257
31. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: The Odense Study. Andersen K, Nielsen H, Lolk A, Andersen J, Becker I, Kragh-Sorensen P NEUROLOGY 1999 52 1 85-90
32. Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. Nelson PT, Braak H, Markesbery WR J NEUROPATHOL EXP NEUROL 2009 68 1 1-14
33. The AMyloid hypothesis for Alzheimer's disease: A critical reappraisal. Hardy J J NEUROCHEM 2009 110 4 1129-1134
34. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR SCIENCE 1982 215 4537 1237-1239
35. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of meynert in Parkinson's disease and Alzheimer's disease. Whitehouse PJ ADV NEUROL 1987 45 393-398
36. Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Haroutunian V, Kanof P, Davis KL LIFE SCI 1985 37 10 945-952
37. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis-Effects on performance in the water maze task and cortical cholinergic markers. Mandel RJ, Chen AD, Connor DJ, Thal LJ J PHARMACOL EXP THER 1989 251 2 612-619
38. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. Bassil N, Grossberg GT CNS DRUGS 2009 23 4 293-307
39. Developmental neuroBIOLogy and the natural history of nerve growth factor. Lev-Imontalcini R ANNU REV NEUROSCI 1982 5 341-362
40. Nerve growth factor treatment after brain injury prevents neuronal death. Kromer LF SCIENCE 1987 235 4785 214-216
41. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; Implications for Alzheimer's disease. Hefti F, Will B J NEURAL TRANSM SUPPL 1987 24 309-315
42. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth-factor. Haroutunian V, Kanof PD, Davis KL BRAIN RES 1986 386 1-2 397-399
43. Spatial-learning in rats-Correlation with cortical choline- acetyltransferase and improvement with NGF following NBM damage. Mandel RJ, Gage FH, Thal LJ EXP NEUROL 1989 104 3 208-217
44. Neurotrophin-regulated signalling pathways. Reichardt LF PHILOS TRANS R SOC LOND B-BIOL SCI 2006 361 1473 1545-1564
45. Cholinergic innervation of cortex by the basal forebrain-Cyto-chemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalAMus in the rhesus-monkey. MesulAM MM, Mufson EJ, Levey AI, Wainer BH J COMP NEUROL 1983 214 2 170-197
46. Nerve growth-factor receptor immunoreactive profiles in the normal, aged human basal forebrain-Colocalization with cholinergic neurons. Mufson EJ, Bothwell M, Hersh LB, Kordower JH J COMP NEUROL 1989 285 2 196-217
47. Viral vectors for in vivo gene transfer in Parkinson's disease: Properties and Clinical grade production. Mandel RJ, Burger C, Snyder RO EXP NEUROL 2008 209 1 58-71
48. Dose and promoter Effects of adeno-associated viral vector for green fuorescent protein expression in the rat brain. Klein RL, HAMby ME, Gong Y, Hirko AC, Wang S, Hughes JA, King MA, Meyer EM EXP NEUROL 2002 176 1 66-74
49. The cholinergic hypothesis: A historical overview, current perspective, and future directions. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C ANN NY ACAD SCI 1985 444 332-358
50. Intracerebral NGF infusion induces hyperinnervation of cerebral blood vessels. Isaacson LG, Saffiran BN, Crutcher KA NEUROBIOL AGING 1990 11 1 51-55
51. 1073810 NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Klein RL, Hirko AC, Meyers CA, Grimes JR, Muzyczka N, Meyer EM BRAIN RES 2000 875 1-2 144-151
52. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Nagahara AH, Bernot T, Moseanko R, Moseanko R, Brignolo L, Blesch A, Conner JM, RAMirez A, Gasmi M, Tuszynski MH EXP NEUROL 2009 215 1 153-159
53. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nithianantharajah J, Hannan AJ NAT REV NEUROSCI 2006 7 9 697-709
54. Treatment of Parkinson's disease with trophic factors. Peterson AL, Nutt JG NEUROTHERAPEUTICS 2008 5 2 270-280
55. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP NAT REV DRUG DISCOv 2009 8 9 733-750
56. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: Comparison between intraparenchymal and intraventricular administration. Venero JL, Hefti F, Knusel B MOL PHARMACOL 1996 49 2 303-310
57. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Winkler J, RAMirez GA, Kuhn HG, Peterson DA, DayLollini PA, Stewart GR, Tuszynski MH, Gage FH, Thal LJ ANN NEUROL 1997 41 1 82-93
58. The effects of rAAV2-mediated NGF gene delivery in adult and aged rats. Wu K, Meyers CA, Guerra NK, King MA, Meyer EM MOL THER 2004 9 2 262-269
59. AAV2/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy. Wu K, Meyer EM, Bennett JA, Meyers CA, Hughes JA, King MA BRAIN RES 2005 1061 2 107-113
60. Long-term neuronal effects and disposition of ectopic preproNGF gene transfer into the rat septum. Wu K, Klein RL, Meyers CA, King MA, Hughes JA, Millard WJ, Meyer EM HUM GENE THER 2003 14 15 1463-1472
61. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Aken KAWV, Hobbs JA, Zolotukhin S, Muzyczka N et al VIROLOGY 2008 381 2 194-202
62. The role of basal forebrain neurons in tonic and phasic activation of the cerebral cortex. Detari L, Rasmusson DD, Semba K PROG NEUROBIOL 1999 58 3 249-277
63. The role of cortical cholinergic afferent projections in cognition: Impact of new selective immunotoxins. McGaughy J, Everitt BJ, Robbins TW, Sarter M BEHAV BRAIN RES 2000 115 2 251-263
64. CERE-110 for Alzheimer's disease. Bennett DA RECOMBINANT DNA ADVISORY COMMITTEE MEET 2004 March 11
65. A phase I/II, dose-escalating, randomized and controlled study to assess the safety, tolerability, and efficacy of CERE-110 (adeno-associated virus [AAV]-based, vector-mediated delivery of β-nerve growth factor [NGF]) in subjects with mild to moderate Alzheimer's disease. Bartus RT RECOMBINANT DNA ADvISORY COMMITTEE MEET 2005 March 16
66. CERE-110 nonCLINical studies. Bartus RT RECOMBINANT DNA ADVISORY COMMITTEE MEET 2004 March 11
67. CERE-110, a genetically engineered adeno-associated virus-based vector to deliver human β-nerve growth factor. Bennett DA, Bakay R RECOMBINANT DNA ADVISORY COMMITTEE MEET 2004 March 11
68. Nontropic actions of neurotrophins: Subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation, Conner JM, Darracq MA, Roberts J, Tuszynski MH PROC NATL ACAD SCI USA 2001 98 4 1941-1946
69. Update on Alzheimer's disease. Dubois B ANN PHARM FR 2009 67 2 116-126